Mesa Laboratories, Inc. announced that President and Chief Executive Officer Gary Owens will step down on April 12, 2026, and that Chief Operating Officer Siddhartha Kadia will assume the CEO role and join the Board of Directors effective April 13, 2026.
Owens has led Mesa since 2017, guiding the company through significant growth and the implementation of its "Mesa Way" business system. Kadia, who has scaled life‑science businesses as CEO of Calibre Scientific and EAG Laboratories, brings a track record of commercializing innovative technologies and managing large, complex organizations.
In its most recent earnings release, Mesa reported Q3 FY2026 revenue of $65.13 million, up 3.6% organically (1.2% core organic) versus the prior year and 5.7% when excluding China‑based Clinical Genomics revenue. Total company growth was 7.2% sequentially, and the company’s adjusted operating income (AOI) excluding unusual items rose to 26.2% of revenue, up from 23.5% in both Q3 FY2025 and the full year FY2025. The earnings beat analyst expectations by $0.66 per share, driven by strong demand in core quality‑control businesses, pricing power, and disciplined cost management.
Mesa Laboratories operates through four divisions—Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics. The Q3 results reflected robust performance across these segments, with the company’s focus on high‑margin quality‑control solutions underpinning revenue growth and margin expansion.
Management highlighted the stability of end markets and the company’s adaptability: "Steady execution and relatively stable markets across Europe and North America helped deliver 3.6% organic revenues growth in 3Q26 versus the prior year, or 5.7% when excluding CG China revenues. Total company growth was 7.2% sequentially, well within our expected growth range," said Owens. He added, "Profitability for the quarter, using our preferred metric of AOI excluding unusual items as a percentage of revenues, was very robust at 26.2% versus 23.5% for both 3Q25 and the whole of FY25. While macro conditions in the first three quarters of FY26 were challenging, we remain encouraged that end markets are stabilizing, our innovative solutions remain top of mind with customers, and our highly adaptable operating model and team will enable us to further accelerate both top and bottom‑line growth as market conditions improve."
The transition is described as a planned succession, with Kadia’s appointment signaling confidence in continued growth and execution. His experience scaling life‑science businesses and his new role on the board position him to drive Mesa’s strategic focus on core quality‑control offerings and high‑margin segments, reinforcing investor confidence in the company’s long‑term trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.